Journal of the American Society of Nephrology, Vol 4, 1814-1819, Copyright © 1994 by American Society of Nephrology

REGULAR ARTICLES

A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia

K Amann, E Ritz, G Wiest, G Klaus and G Mall
Department of Pathology, Ruperto Carola University, Heidelberg, Germany.

Intermyocardiocytic fibrosis, i.e., nonreparative interstitial fibrosis with collagen fiber deposition, is commonly found in uremic patients and animals. The volume density of interstitial tissue in the left papillary muscle of uremic animals was found to be increased (from 1.9 +/- 0.7 to 4.2 +/- 1.1%; P < 0.001). The nuclei of interstitial cells, but not of endothelial cells, were enlarged, pointing to an activating signal that specifically acts on interstitial cells. Because of the known action of parathyroid hormone (PTH) on the heart, a potential role of PTH in the genesis of fibrosis was explored by comparing subtotally nephrectomized (NX) parathyroidectomized (PTX) rats receiving by osmotic minipump either saline or rat 1,34 PTH (100 ng/kg per hour dissolved in NaCl). Animals were on a standard 0.95% Ca diet. After PTX, they were switched to a high-calcium (3%) diet. At the end of the 14-day experiments, NX-PTX-PTH animals and NX-PTX-solvent animals were comparable with respect to mean body weight (335 versus 338 g), serum creatinine (1.2 versus 1.2 mg/dL), and serum-Ca (2.66 versus 2.63 mmol/L). The volume densities of cardiac interstitium were 4.71 +/- 0.87 versus 1.49 +/- 0.49, and those of capillaries were 8.07 +/- 1.54 versus 7.94 +/- 2.62, respectively (P < 0.001 by analysis of variance). Thus, PTX abolished and PTH restored intermyocardiocytic changes of experimental uremia. These observations argue for a permissive role of PTH for fibroblast activation and the genesis of the cardiac fibrosis of uremia.

This article has been cited by other articles:

				A. Covic, P. Kothawala, M. Bernal, S. Robbins, A. Chalian, and D. Goldsmith Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease Nephrol. Dial. Transplant., November 11, 2008; (2008) gfn613v1. [Abstract] [Full Text] [PDF]

				N. Koleganova, G. Piecha, E. Ritz, and M.-L. Gross Calcitriol ameliorates capillary deficit and fibrosis of the heart in subtotally nephrectomized rats Nephrol. Dial. Transplant., October 1, 2008; (2008) gfn549v1. [Abstract] [Full Text] [PDF]

				D. E. Wallis, S. Penckofer, and G. W. Sizemore The "Sunshine Deficit" and Cardiovascular Disease Circulation, September 30, 2008; 118(14): 1476 - 1485. [Full Text] [PDF]

				H. Ogata, M. Mizobuchi, F. Koiwa, E. Kinugasa, and T. Akizawa Clinical significance of parathyroid intervention on CKD-MBD management NDT Plus, August 1, 2008; 1(suppl_3): iii9 - iii13. [Abstract] [Full Text] [PDF]

				V. Dilsizian and J. C. Fink Deleterious Effect of Altered Myocardial Fatty Acid Metabolism in Kidney Disease J. Am. Coll. Cardiol., January 15, 2008; 51(2): 146 - 148. [Full Text] [PDF]

				W. Marz, U. Seelhorst, B. Wellnitz, B. Tiran, B. Obermayer-Pietsch, W. Renner, B. O. Boehm, E. Ritz, and M. M. Hoffmann Alanine to Serine Polymorphism at Position 986 of the Calcium-Sensing Receptor Associated with Coronary Heart Disease, Myocardial Infarction, All-Cause, and Cardiovascular Mortality J. Clin. Endocrinol. Metab., June 1, 2007; 92(6): 2363 - 2369. [Abstract] [Full Text] [PDF]

				G. Rashid, J. Bernheim, J. Green, and S. Benchetrit Cardiovascular Events and Parathyroid Hormone--Suggestion of a Further Link J. Am. Soc. Nephrol., April 1, 2007; 18(4): 1023 - 1026. [Abstract] [Full Text] [PDF]

				K. Amann, C. Wanner, and E. Ritz Cross-Talk between the Kidney and the Cardiovascular System J. Am. Soc. Nephrol., August 1, 2006; 17(8): 2112 - 2119. [Abstract] [Full Text] [PDF]

				C. P. Schmitt, T. Odenwald, and E. Ritz Calcium, Calcium Regulatory Hormones, and Calcimimetics: Impact on Cardiovascular Mortality J. Am. Soc. Nephrol., April 1, 2006; 17(4_suppl_2): S78 - S80. [Abstract] [Full Text] [PDF]

				S. Y. Hayashi, M. Rohani, B. Lindholm, L.-A. Brodin, B. Lind, P. Barany, A. Alvestrand, and A. Seeberger Left ventricular function in patients with chronic kidney disease evaluated by colour tissue Doppler velocity imaging Nephrol. Dial. Transplant., January 1, 2006; 21(1): 125 - 132. [Abstract] [Full Text] [PDF]

				M. C. Matteucci, E. Wuhl, S. Picca, A. Mastrostefano, G. Rinelli, C. Romano, G. Rizzoni, O. Mehls, G. de Simone, F. Schaefer, et al. Left Ventricular Geometry in Children with Mild to Moderate Chronic Renal Insufficiency J. Am. Soc. Nephrol., January 1, 2006; 17(1): 218 - 226. [Abstract] [Full Text] [PDF]

				Y. Slinin, R. N. Foley, and A. J. Collins Calcium, Phosphorus, Parathyroid Hormone, and Cardiovascular Disease in Hemodialysis Patients: The USRDS Waves 1, 3, and 4 Study J. Am. Soc. Nephrol., June 1, 2005; 16(6): 1788 - 1793. [Abstract] [Full Text] [PDF]

				B. Kestenbaum, J. N. Sampson, K. D. Rudser, D. J. Patterson, S. L. Seliger, B. Young, D. J. Sherrard, and D. L. Andress Serum Phosphate Levels and Mortality Risk among People with Chronic Kidney Disease J. Am. Soc. Nephrol., February 1, 2005; 16(2): 520 - 528. [Abstract] [Full Text] [PDF]

				G. de Simone Left Ventricular Geometry and Hypotension in End-Stage Renal Disease: A Mechanical Perspective J. Am. Soc. Nephrol., October 1, 2003; 14(10): 2421 - 2427. [Abstract] [Full Text] [PDF]

				H. Ogata, E. Ritz, G. Odoni, K. Amann, and S. R. Orth Beneficial Effects of Calcimimetics on Progression of Renal Failure and Cardiovascular Risk Factors J. Am. Soc. Nephrol., April 1, 2003; 14(4): 959 - 967. [Abstract] [Full Text] [PDF]

				G. M. London, S. J. Marchais, A. P. Guerin, F. Metivier, and H. Adda Arterial structure and function in end-stage renal disease Nephrol. Dial. Transplant., October 1, 2002; 17(10): 1713 - 1724. [Full Text] [PDF]

				S. K. GANESH, A. G. STACK, N. W. LEVIN, T. HULBERT-SHEARON, and F. K. PORT Association of Elevated Serum PO4, Ca PO4 Product, and Parathyroid Hormone with Cardiac Mortality Risk in Chronic Hemodialysis Patients J. Am. Soc. Nephrol., October 1, 2001; 12(10): 2131 - 2138. [Abstract] [Full Text] [PDF]

				A. T. KAUSZ, S. S. KHAN, R. ABICHANDANI, W. H. KAZMI, G. T. OBRADOR, R. RUTHAZER, and B. J. G. PEREIRA Management of Patients with Chronic Renal Insufficiency in the Northeastern United States J. Am. Soc. Nephrol., July 1, 2001; 12(7): 1501 - 1507. [Abstract] [Full Text] [PDF]

				R. J. MIDDLETON, P. S. PARFREY, and R. N. FOLEY Left Ventricular Hypertrophy in the Renal Patient J. Am. Soc. Nephrol., May 1, 2001; 12(5): 1079 - 1084. [Full Text]

				P. DONOHOE, B. M. HENDRY, O. V. WALGAMA, F. BERTASO, D. J. HOPSTER, M. J. SHATTOCK, and A. F. JAMES An Altered Repolarizing Potassium Current in Rat Cardiac Myocytes after Subtotal Nephrectomy J. Am. Soc. Nephrol., September 1, 2000; 11(9): 1589 - 1599. [Abstract] [Full Text]

				A. U. Klingbeil and R. E. Schmieder Not all left ventricular hypertrophy is created equal Nephrol. Dial. Transplant., December 1, 1999; 14(12): 2803 - 2805. [Full Text] [PDF]

				K. Amann, M.-L. Gross, G. M. London, and E. Ritz Hyperphosphataemia—a silent killer of patients with renal failure? Nephrol. Dial. Transplant., September 1, 1999; 14(9): 2085 - 2087. [Full Text] [PDF]

				S. J. Marchais, F. Metivier, A. P. Guerin, and G. M. London Association of hyperphosphataemia with haemodynamic disturbances in end-stage renal disease Nephrol. Dial. Transplant., September 1, 1999; 14(9): 2178 - 2183. [Abstract] [Full Text] [PDF]

				V. Di Bello, V. Panichi, R. Pedrinelli, D. Giorgi, M. Bianchi, A. Bertini, D. Taccola, S. De Pietro, E. Talini, M. Paterni, et al. Ultrasonic videodensitometric analysis of myocardium in end-stage renal disease treated with haemodialysis Nephrol. Dial. Transplant., September 1, 1999; 14(9): 2184 - 2191. [Abstract] [Full Text] [PDF]

				R. VANHOLDER and R. DE SMET Pathophysiologic Effects of Uremic Retention Solutes J. Am. Soc. Nephrol., August 1, 1999; 10(8): 1815 - 1823. [Full Text]

				I. LORINCZ, J. MÁTYUS, Z. ZILAHI, C. KUN, Z. KARÁNYI, and G. KAKUK QT Dispersion in Patients with End-Stage Renal Failure and during Hemodialysis J. Am. Soc. Nephrol., June 1, 1999; 10(6): 1297 - 1302. [Abstract] [Full Text]

				K. Amann, B. Wolf, C. Nichols, J. Tornig, U. Schwarz, M. Zeier, G. Mall, and E. Ritz Aortic Changes in Experimental Renal Failure: Hyperplasia or Hypertrophy of Smooth Muscle Cells? Hypertension, March 1, 1997; 29(3): 770 - 775. [Abstract] [Full Text]

				T. Stefenelli, C. Abela, H. Frank, J. Koller-Strametz, S. Globits, J. Bergler-Klein, and B. Niederle Cardiac Abnormalities in Patients with Primary Hyperparathyroidism: Implications for Follow-Up J. Clin. Endocrinol. Metab., January 1, 1997; 82(1): 106 - 112. [Abstract] [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673